Wire · opportunities
Roche's Gazyva Secures FDA Approval For Primary Membranous Nephropathy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 November 2026 · Fusion42 review
Roche's drug Gazyva has received FDA approval for treating primary membranous nephropathy, expanding its therapeutic indications.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 14 Nov 2026 and 16 Nov 2026.
◆ ◆ The Wire takeaway
You face a clearer regulatory pathway for nephropathy treatments that now includes Gazyva as a precedent. Competing or complementary biotech ventures can benchmark against Roche’s expanded label to strategise market entry.
◆ Coverage
2 sources · first reported 14 Nov 2026 · latest 16 Nov 2026
◆ Related on Wire
◆ Topics